The analyst notes that VASC reported revenue of $41.2M, marginally above consensus estimates of $41.1M. In addition, the company reported adjusted EPS above consensus estimates.
West explains, “Without the distraction from the Short Kit litigation and with continued strong organic revenue growth from its existing product portfolio, the ~ $100M RePlas opportunity, and the potential for continued organic operating leverage (600-800bps pre-RePlas), we expect VASC shares to continue to work. We raise our target to $49 ($45 prior).”
According to TipRanks, Brooks West is ranked #375 of 4,079 analysts. West maintains a success rate of 71% with an average return of 10.2%.